Brasiūniene B, Juozaityte E, Inciūra A, Brasiūnas V, Barauskas G
Clinic of Oncology, Clinic of Surgery, Kaunas University of Medicine, Lithuania.
Rocz Akad Med Bialymst. 2003;48:66-9.
To assess the benefit of treatment modalities on the survival in patients with pancreatic cancer.
Eighty-five patients with pancreatic cancer were treated by surgery, radiotherapy, chemotherapy and combined therapy. The data was reviewed retrospectively and the benefit of various treatment methods to the median survival time of the patients was assessed.
Median survival time of the patients diagnosed with local disease treated by radical resection and adjuvant treatment was 21.5 months; with radical resection only--12.6 months (p = 0.6). In patients with locally advanced disease and treated by radical resection and adjuvant therapies the median survival time was 12.1 months and by radical resection only 7.7 months (p = 0.6). For patients treated by palliative surgery, chemotherapy and radiotherapy median survival was 8.8 months and by palliative surgery alone 1.8 month (p = 0.015). 1-year actual survival of patients treated with radical resection and adjuvant therapies was 11.7%. For patients with radical resection only--10.5%. 3-year actual survival for the same groups of patients was 3.5% and 2.3%, respectively. 1-year actual survival of patients treated by palliative methods was 2.3%.
Surgery with adjuvant treatment seems to be beneficial for pancreatic adenocarcinoma patients. In locally advanced and metastatic pancreatic cancer palliative chemotherapy or radiotherapy statistically significantly improved survival.
评估治疗方式对胰腺癌患者生存的益处。
85例胰腺癌患者接受了手术、放疗、化疗及联合治疗。对数据进行回顾性分析，评估各种治疗方法对患者中位生存时间的益处。
经根治性切除及辅助治疗的局部病变患者中位生存时间为21.5个月；仅行根治性切除的患者为12.6个月（p = 0.6）。局部进展期疾病患者经根治性切除及辅助治疗的中位生存时间为12.1个月，仅行根治性切除的为7.7个月（p = 0.6）。接受姑息性手术、化疗及放疗的患者中位生存时间为8.8个月，仅行姑息性手术的为1.8个月（p = 0.015）。接受根治性切除及辅助治疗的患者1年实际生存率为11.7%。仅行根治性切除的患者为10.5%。同一组患者的3年实际生存率分别为3.5%和2.3%。接受姑息性治疗的患者1年实际生存率为2.3%。
手术联合辅助治疗似乎对胰腺腺癌患者有益。在局部进展期和转移性胰腺癌中，姑息性化疗或放疗在统计学上显著提高了生存率。
